Geron (GERN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.02
- Estimate
- -$0.01
- Surprise
- -146.4%
- Revenue (period 2026-06-30)
- $57.5M
- Score today
- 5.5/10
Revenue source: mixed.
How the report landed
Geron (GERN) reported a wider loss than forecast — adjusted EPS of -$0.02 against the -$0.01 estimate (a 146.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates GERN Sell at 5.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -146.4% surprise compares with a +1.6% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: RYTELO (imetelstat)
- DATA_ISSUE: analyst_target_implausible (raw $4.25 vs price $1.23 — ratio 3.5×). Rejected, falling back to technical TP.
- Quality below floor (3.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1.23
- Price target
- $1.30
- Stop
- $1.15
- Upside to target
- +5.7%
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
GERN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $764.5M
- P/E (fwd)
- 29.8
- 52-week range
- $1.04–$2.01
- Off 52-week high
- 38.8%
- RSI (14)
- 42
- Volume vs avg
- 0.63×
- Score today
- 5.5/10